2023
DOI: 10.1136/bmjopen-2023-075197
|View full text |Cite
|
Sign up to set email alerts
|

Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study

Abstract: IntroductionPsoriasis is a chronic inflammatory skin disease. Adalimumab is an effective but previously expensive biological treatment for psoriasis. The introduction of biosimilars following the patent expiry of the originator adalimumab Humira has reduced the unit cost of treatment. However, the long-term effectiveness and safety of adalimumab biosimilars for treating psoriasis in real-world settings are uncertain and may be a barrier to widespread usage.Methods and analysisThis study aims to compare the dru… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 24 publications
0
0
0
Order By: Relevance